Keep up to Date and Stay Informed

Sign up for email alerts to receive company updates including press releases, filings and special announcements straight to your inbox.

Sign me up for:

Latest Financial Results

Q1 2020

Quarter Ended Mar 31, 2020

Latest 10-K

View Latest 10-K

Stock Information

Symbol

Nasdaq: CWBR

Price

Change

Volume

52 week Low/High

Day Low/High

Company Overview

CohBar (NASDAQ: CWBR) is a clinical stage biotechnology company focused on the research and development of mitochondria based therapeutics, an emerging class of drugs for the treatment of chronic and age-related diseases. Mitochondria based therapeutics originate from the discovery by CohBar’s founders of a novel group of naturally occurring mitochondrial-derived peptides within the mitochondrial genome that regulate metabolism and cell death, and whose biological activity declines with age. To date, the company has discovered more than 100 mitochondrial derived peptides and generated over 1,000 analogs. CohBar’s efforts focus on the development of these peptides into therapeutics that offer the potential to address a broad range of diseases, including nonalcoholic steatohepatitis (NASH), obesity, fibrotic diseases, cancer, acute respiratory distress syndrome (ARDS), type 2 diabetes, and cardiovascular and neurodegenerative diseases. The company’s lead compound, CB4211, is in the Phase 1b stage of a Phase 1a/1b clinical trial for NASH and obesity. This clinical trial is currently paused due to the COVID-19 pandemic. In addition, CohBar has four preclinical programs, two in cancer, one in fibrotic diseases and one in COVID-19 associated ARDS and type 2 diabetes.

July 2020 Corporate Presentation

July 2020 Corporate Presentation

Download

CohBar Team: Experienced Biotech Executives & Scientists

Our leadership team is comprised of experienced scientists and biotech executives who manage and guide the Company's research and development, financing, partnering and strategic plans.

Investor Contact Information

Company

CohBar, Inc.
1455 Adams Drive
Suite 2050
Menlo Park, CA 94025
T: (650) 446-7888

Investor Relations

Jordyn Tarazi
Director, Investor Relations
T: (650) 445-4441
jordyn.tarazi@cohbar.com

Transfer Agent

American Stock Transfer & Trust Company (Canada)
1066 West Hastings Street
Suite 1600
Vancouver, BC V6E 3X1